Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
8.72
-0.01 (-0.06%)
Feb 20, 2025, 11:54 AM EST - Market open
Anavex Life Sciences Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
| TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 |
Selling, General & Admin | 11.62 | 11.16 | 12.16 | 13.14 | 9.15 | 6.09 | |
Research & Development | 41.36 | 39.42 | 40.88 | 34.52 | 28.31 | 20.62 | |
Operating Expenses | 52.98 | 50.59 | 53.04 | 47.66 | 37.46 | 26.71 | |
Operating Income | -52.98 | -50.59 | -53.04 | -47.66 | -37.46 | -26.71 | |
Interest & Investment Income | 6.71 | 7.32 | 6.52 | 0.95 | 0.03 | 0.18 | |
Currency Exchange Gain (Loss) | -0.3 | 0.19 | -0.04 | -0.9 | -0.27 | 0.13 | |
Other Non Operating Income (Expenses) | 0.09 | 0.08 | -0.04 | - | 0.05 | 0.15 | |
EBT Excluding Unusual Items | -46.49 | -43 | -46.6 | -47.62 | -37.64 | -26.26 | |
Other Unusual Items | - | - | -0.9 | - | - | - | |
Pretax Income | -46.49 | -43 | -47.5 | -47.62 | -37.64 | -26.26 | |
Income Tax Expense | - | - | 0.01 | 0.36 | 0.27 | 0.02 | |
Net Income | -46.49 | -43 | -47.51 | -47.98 | -37.91 | -26.28 | |
Net Income to Common | -46.49 | -43 | -47.51 | -47.98 | -37.91 | -26.28 | |
Shares Outstanding (Basic) | 84 | 83 | 80 | 77 | 70 | 58 | |
Shares Outstanding (Diluted) | 84 | 83 | 80 | 77 | 70 | 58 | |
Shares Change (YoY) | 4.13% | 4.61% | 3.74% | 10.18% | 19.95% | 18.99% | |
EPS (Basic) | -0.55 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 | |
EPS (Diluted) | -0.55 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 | |
Free Cash Flow | -35.61 | -30.81 | -27.79 | -24.24 | -30.38 | -21.29 | |
Free Cash Flow Per Share | -0.42 | -0.37 | -0.35 | -0.32 | -0.44 | -0.37 | |
EBIT | -52.98 | -50.59 | -53.04 | -47.66 | -37.46 | -26.71 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.